Stock comparison
Halozyme Therapeutics
TransMedics Group
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.41B
Sector
Healthcare
TMDX
TransMedics Group
Market cap
$2.18B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | TMDX | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 51C | HALO |
| Benjamin Graham | 73B | 55C | HALO |
| Philip Fisher | 55C | 54C | HALO |
| Peter Lynch | 43D | 87A | TMDX |
| Joel Greenblatt | 30F | 42D | TMDX |
| Charlie Munger | 70B | 48D | HALO |
| Terry Smith | 74B | 41D | HALO |
Side-by-side metrics
| Metric | HALO | TMDX |
|---|---|---|
| Market cap | $8.41B | $2.18B |
| P/E (TTM) | 24.0x | 12.6x |
| EV/EBIT | 10.2x | 23.4x |
| ROIC (TTM) | 23.65% | 6.94% |
| Gross margin | 81.24% | 59.09% |
| Net margin | 23.13% | 27.04% |
| Revenue CAGR 5y | 33.23% | 111.5% |
| EPS CAGR 5y | -1.98% | - |
| Debt / Equity | 1.0x | 1.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Market cap$8.41Bvs $2.18B+74%
- ROIC (TTM)23.65%vs 6.94%+71%
- EV/EBIT10.2xvs 23.4x+56%
- Debt / Equity1.0xvs 1.7x+43%
TMDX leads on
- Revenue CAGR 5y111.5%vs 33.23%+70%
- P/E (TTM)12.6xvs 24.0x+47%
- Net margin27.04%vs 23.13%+14%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.